Triple Therapy Provides Robust and Durable Benefits in Cystic Fibrosis
Triple combination therapy with elexacaftor, ivacaftor, and tezacaftor has advantages over tezacaftor plus ivacaftor in people with cystic fibrosis, according to results of a phase 3b trial.
Reuters Health Information
source https://www.medscape.com/viewarticle/965830?src=rss
Reuters Health Information
source https://www.medscape.com/viewarticle/965830?src=rss
Comments
Post a Comment